Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature

Nishitha Thumallapally, Hana Yu, Mohammad Farhan, Uroosa Ibrahim, Maricel Odiami

Research output: Contribution to journalArticle

1 Scopus citations


Empirical evidence has long suggested that oncogenic driver mutations in non-small-cell lung cancer are mutually independent. However, recent studies reported in pertinent literature reveal that concomitant epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangement can occur in a subset of patients with NSCLC. In order to shed further light on this issue, we report a case of adenocarcinoma of lung harboring both EGFR mutation in exon 21 (L861Q) and ALK rearrangement. This allows us to speculate on likely molecular mechanisms underlying this uncommon phenomenon, while also offering some practical guidelines on the therapeutic options that could benefit patients diagnosed with this dual-positive tumor.

Original languageEnglish (US)
Pages (from-to)244-248
Number of pages5
JournalJournal of Pharmacy Practice
Issue number2
Publication statusPublished - Apr 1 2018
Externally publishedYes



  • acquired resistance
  • adenocarcinoma
  • ALK
  • concomitant
  • driver mutation
  • EGFR
  • lung

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this